Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fortress Biotech, Inc. (FBIO)
USD3.71
-0.02 (-0.54%)
US NASDAQ Healthcare Biotechnology
Address
1111 Kane Concourse 33154
Bay Harbor Islands, FL, US
Bay Harbor Islands, FL, US
CEO
Lindsay Allan Rosenwald
Website
fortressbiotech.com
IPO
2011-11-17
CIK 1429260 ISIN US34960Q3074
Also trades on
NASDAQ Capital Market · FBIO (USD)
NASDAQ Capital Market · FBIOP (USD)
Description
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.71
-0.02 (-0.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
438.2K
Beta
1.21
Float Shares
24.35M
Free Float %
75.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.78% | +0.84% | +2.12% | -31.14% | -7.66% | -34.15% | +36.93% | -76.37% | -95.46% | -94.38% | -98.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
3.71
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.85
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+9.7% ★ Q1'26: +22.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+97.5% ★ Q1'26: +687.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-155.2% Q1'26: +1,271.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-111.0% Q1'26: -48.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-123.0% Q1'26: -18,649.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,242.5% Q1'26: +45.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.17× Q1'26: -1.73× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
863.0K
est: 500.0K (+72.6%)
|
16.48M
est: 22.30M (-26.1%)
|
187.58M
est: 189.60M (-1.1%)
|
26.88M
est: 246.20M (-89.1%)
|
36.63M
est: 36.96M (-0.9%)
|
45.60M
est: 43.83M (+4.0%)
|
68.79M
est: 89.50M (-23.1%)
|
75.74M
est: 77.97M (-2.9%)
|
84.51M
est: 85.11M (-0.7%)
|
57.68M
est: 57.13M (+0.9%)
|
63.26M
est: 73.34M (-13.7%)
|
96.27M
94.24M – 98.30M
+31.3% YoY
|
125.31M
122.67M – 127.96M
+30.2% YoY
|
| EBITDA |
-52.37M
est: -500.0K (-10,374.6%)
|
-66.87M
est: -22.30M (-199.9%)
|
-88.57M
est: -189.60M (+53.3%)
|
-118.40M
est: -246.20M (+51.9%)
|
-88.48M
est: -36.96M (-139.4%)
|
-87.82M
est: -43.83M (-100.3%)
|
-146.17M
est: -89.50M (-63.3%)
|
-193.69M
est: -77.97M (-148.4%)
|
-135.72M
est: -85.11M (-59.5%)
|
-104.49M
est: -57.13M (-82.9%)
|
-63.62M
est: -73.34M (+13.3%)
|
-96.27M
-98.30M – -94.24M
-31.3% YoY
|
-125.31M
-127.96M – -122.67M
-30.2% YoY
|
| EBIT |
-52.40M
est: -500.0K (-10,379.8%)
|
-67.60M
est: -22.30M (-203.1%)
|
-89.83M
est: -189.60M (+52.6%)
|
-120.46M
est: -246.20M (+51.1%)
|
-93.13M
est: -36.96M (-152.0%)
|
-93.15M
est: -43.83M (-112.5%)
|
-152.96M
est: -89.50M (-70.9%)
|
-203.05M
est: -77.97M (-160.4%)
|
-141.72M
est: -85.11M (-66.5%)
|
-108.96M
est: -57.13M (-90.7%)
|
-70.22M
est: -73.34M (+4.3%)
|
-96.27M
-98.30M – -94.24M
-31.3% YoY
|
-125.31M
-127.96M – -122.67M
-30.2% YoY
|
| Net Income |
-48.43M
est: -180.82M (+73.2%)
|
-55.10M
est: -355.41M (+84.5%)
|
-66.88M
est: -634.95M (+89.5%)
|
-84.15M
est: -611.05M (+86.2%)
|
-39.96M
est: -231.33M (+82.7%)
|
-46.53M
est: -226.55M (+79.5%)
|
-64.70M
est: -114.31M (+43.4%)
|
-86.58M
est: -272.79M (+68.3%)
|
-60.64M
est: -122.08M (+50.3%)
|
-46.00M
est: -978.43M (+95.3%)
|
6.82M
est: 87.89M (-92.2%)
|
-195.31M
-200.68M – -189.95M
-322.2% YoY
|
-139.51M
-143.34M – -135.68M
+28.6% YoY
|
| SGA |
21.58M
est: 670.2K (+3,120.5%)
|
32.92M
est: 29.89M (+10.1%)
|
73.02M
est: 254.14M (-71.3%)
|
53.37M
est: 330.01M (-83.8%)
|
55.59M
est: 49.54M (+12.2%)
|
61.17M
est: 58.75M (+4.1%)
|
86.84M
est: 119.97M (-27.6%)
|
113.66M
est: 104.51M (+8.7%)
|
90.98M
est: 114.09M (-20.3%)
|
87.73M
est: 78.59M (+11.6%)
|
96.00M
est: 100.89M (-4.8%)
|
132.43M
129.63M – 135.23M
+31.3% YoY
|
172.38M
168.74M – 176.02M
+30.2% YoY
|
| EPS |
-18.56
est: -8.70 (-113.3%)
|
-20.68
est: -17.10 (-20.9%)
|
-24.08
est: -30.55 (+21.2%)
|
-29.04
est: -29.40 (+1.2%)
|
-10.95
est: -11.13 (+1.6%)
|
-9.75
est: -10.90 (+10.6%)
|
-11.85
est: -5.50 (-115.5%)
|
-14.55
est: -13.13 (-10.9%)
|
-8.47
est: -5.87 (-44.2%)
|
-2.69
est: -3.51 (+23.3%)
|
-0.07
est: 0.32 (-121.4%)
|
-0.70
-0.72 – -0.68
-322.2% YoY
|
-0.50
-0.51 – -0.49
+28.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-63.34M
OE per share TTM
-1.83
Owner's Yield
-101.80%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
43.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
5.82M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fortress Biotech, Inc. | 10.01M | 56.90% | 10.01M | — | 10.01M | — | HC | — | 2022-08-17 | ↗ |
| 2 | Daniel Mack | 9.09M | 9.60% | — | 9.09M | — | — | HC | USA | 2022-02-14 | ↗ |
| 3 | Nantahala Capital Management, LLC | 9.09M | 9.60% | — | 9.09M | — | — | IA | MA | 2022-02-14 | ↗ |
| 4 | Wilmot B. Harkey | 9.09M | 9.60% | — | 9.09M | — | — | HC | USA | 2022-02-14 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 5.69M | 5.71% | — | 129.5K | — | 160.0K | IA | Pennsylvania | 2022-02-10 | ↗ |
| 6 | DAK Capital Inc. | 5.61M | 5.87% | — | 5.61M | — | 5.61M | CO | Alberta, Canada | 2020-12-28 | ↗ |
| 7 | Mr. Daryl Katz | 5.61M | 5.87% | — | 5.61M | — | 5.61M | IN | Canada | 2020-12-28 | ↗ |
| 8 | (1) BlackRock, Inc. | 4.81M | 5.00% | 4.76M | — | 4.81M | — | HC | Delaware | 2021-05-07 | ↗ |
| 9 | Fortress Biotech, Inc. 20-5157386 | 3.84M | 23.30% | 3.84M | — | 3.51M | 10.00 | HC | Citizenship or Place of Organization | 2019-04-19 | ↗ |
| 10 | Edward C. Johnson 3d | 3.02M | 12.38% | — | — | 3.02M | — | IN | Delaware | 2013-03-11 | ↗ |
| 11 | Highbridge Capital Management, LLC | 2.73M | 9.00% | — | 2.73M | — | — | IA, OO | State of Delaware | 2024-10-25 | ↗ |
| 12 | Peter Kolchinsky | 1.74M | 7.10% | 1.74M | — | 1.74M | — | IN | Massachusetts | 2013-02-14 | ↗ |
| 13 | RA Capital Management, LLC | 1.74M | 7.10% | 1.74M | — | 1.74M | — | IA | Massachusetts | 2013-02-14 | ↗ |
| 14 | Elliott International Capital Advisors Inc. | 1.25M | 2.66% | — | 1.25M | — | 1.25M | CO | Cayman Islands British West Indies | 2016-02-16 | ↗ |
| 15 | Elliott International, L.P. | 1.25M | 2.66% | — | 1.25M | — | 1.25M | PN | Cayman Islands British West Indies | 2016-02-16 | ↗ |
| 16 | RA Capital Healthcare Fund, L.P. | 983.4K | 4.00% | 983.4K | — | 983.4K | — | PN | Massachusetts | 2013-02-14 | ↗ |
| 17 | Elliott Associates, L.P. | 645.6K | 1.37% | 645.6K | — | 645.6K | — | PN | Cayman Islands British West Indies | 2016-02-16 | ↗ |
| 18 | Lindsay A. Rosenwald, M.D. | 522.3K | 4.20% | — | 522.3K | — | 10.00 | IN | United States | 2016-05-09 | ↗ |
| 19 | Michael S. Weiss | 522.3K | 4.20% | — | 522.3K | — | 10.00 | IN | United States | 2016-05-09 | ↗ |
| 20 | Opus Point Partners Management, LLC | 522.3K | 4.20% | — | 522.3K | — | 10.00 | OO | Delaware | 2016-05-09 | ↗ |
| 21 | Opus Point Partners, LLC | 522.3K | 4.20% | — | 522.3K | — | 10.00 | OO | Delaware | 2016-05-09 | ↗ |
| 22 | 1 | 9.00 | 11.00% | — | 3.82M | — | 3.82M | IN | Massachusetts | 2019-11-22 | ↗ |
| 23 | DAK Investments Corp. | — | 0.00% | — | — | — | — | CO | Canada | 2018-01-17 | ↗ |
| 24 | FBIO Acquisition, Inc. | — | 0.00% | — | — | — | 10.00 | CO | Delaware | 2019-04-19 | ↗ |
| 25 | FMR LLC | — | 0.00% | — | — | — | — | HC | Delaware | 2013-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
19
-37 vs prev Q
New positions
5
Closed positions
38
Increased
9
Reduced
4
Put/Call ratio
0.00
Calls held
600.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1.10M +150.2K (+15.8%) | 4.03M +516.6K (+14.7%) | 4.04% +0.504 pp | 0.00% +0.000 pp | USD2.58 +41.9% | 9 qtrs — |
| 2 | OPALEYE MANAGEMENT INC. | 1.09M +1.1M (+100.0%) | 3.99M +4.0M (+100.0%) | 4.00% +4.001 pp | 0.53% +0.526 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 3 | SUMMIT FINANCIAL, LLC | 439.9K -4.8K (-1.1%) | 1.61M -35.4K (-2.2%) | 1.61% -0.040 pp | 0.02% -0.002 pp | USD1.86 +96.8% | 3 qtrs — |
| 4 | SHIKIAR ASSET MANAGEMENT INC | 278.5K +— (+0.0%) | 1.02M -11.0K (-1.1%) | 1.02% -0.014 pp | 0.25% -0.005 pp | USD0.83 +341.0% | 10 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 262.5K +18.1K (+7.4%) | 961.1K +57.6K (+6.4%) | 0.96% +0.054 pp | 0.00% +0.000 pp | USD2.24 +63.4% | 9 qtrs — |
| 6 | NORTHERN TRUST CORP | 239.5K +18.9K (+8.6%) | 876.7K +61.4K (+7.5%) | 0.88% +0.058 pp | 0.00% +0.000 pp | USD3.03 +20.8% | 9 qtrs — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 222.8K +148.5K (+199.9%) | 815.4K +540.5K (+196.6%) | 0.82% +0.541 pp | 0.00% +0.000 pp | USD3.31 +10.6% | 9 qtrs — |
| 8 | SCULPTOR CAPITAL LP | 211.4K +2.5K (+1.2%) | 773.7K +1.8K (+0.2%) | 0.78% -0.001 pp | 0.01% -0.001 pp | USD3.70 -1.1% | 2 qtrs — |
| 9 | BLACKROCK, INC. | 200.6K +10.8K (+5.7%) | 734.1K +32.8K (+4.7%) | 0.74% +0.030 pp | 0.00% +0.000 pp | USD2.27 +61.2% | 6 qtrs — |
| 10 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 182.4K +182.4K (+100.0%) | 667.5K +667.5K (+100.0%) | 0.67% +0.669 pp | 0.01% +0.014 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 11 | KESTRA ADVISORY SERVICES, LLC | 175.7K -21.2K (-10.8%) | 643.0K -84.5K (-11.6%) | 0.64% -0.088 pp | 0.00% -0.001 pp | USD1.92 +90.6% | 5 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 139.2K +54.2K (+63.7%) | 509.3K +195.3K (+62.2%) | 0.51% +0.195 pp | 0.00% +0.000 pp | USD3.13 +16.9% | 5 qtrs — |
| 13 | HB WEALTH MANAGEMENT, LLC | 120.2K +— (+0.0%) | 439.8K -4.2K (-0.9%) | 0.44% -0.006 pp | 0.00% 0.000 pp | USD3.70 -1.1% | 6 qtrs — |
| 14 | CI PRIVATE WEALTH, LLC | 96.8K +1.3K (+1.4%) | 354.3K +1.5K (+0.4%) | 0.36% +0.000 pp | 0.00% 0.000 pp | USD3.02 +21.2% | 9 qtrs — |
| 15 | JANE STREET GROUP, LLC | 91.9K +18.8K (+25.7%) | 336.4K +66.3K (+24.6%) | 0.34% +0.065 pp | 0.00% +0.000 pp | USD3.69 -0.8% | 2 qtrs — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 81.1K +40.3K (+98.8%) | 296.8K +146.1K (+96.9%) | 0.30% +0.146 pp | 0.00% +0.000 pp | USD3.68 -0.5% | 6 qtrs — |
| 17 | STATE STREET CORP | 77.3K +8.0K (+11.5%) | 282.8K +26.9K (+10.5%) | 0.28% +0.026 pp | 0.00% +0.000 pp | USD2.95 +24.1% | 9 qtrs — |
| 18 | 180 WEALTH ADVISORS, LLC | 75.9K -6.7K (-8.1%) | 277.6K -27.2K (-8.9%) | 0.28% -0.029 pp | 0.03% -0.006 pp | USD1.72 +112.8% | 7 qtrs — |
| 19 | GROUP ONE TRADING, L.P. | 63.7K +48.3K (+314.1%) | 233.1K +176.3K (+310.2%) | 0.23% +0.177 pp | 0.00% +0.000 pp | USD3.67 -0.3% | 9 qtrs — |
| 20 | CITADEL ADVISORS LLC | 60.9K +60.9K (+100.0%) | 222.9K +222.9K (+100.0%) | 0.22% +0.224 pp | 0.00% +0.000 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 21 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 51.0K +20.3K (+65.9%) | 214.8K +121.0K (+129.0%) | 0.19% +0.073 pp | 0.00% +0.000 pp | USD3.27 +11.9% | 9 qtrs — |
| 22 | PANAGORA ASSET MANAGEMENT INC | 56.7K +20.6K (+56.9%) | 207.4K +74.0K (+55.4%) | 0.21% +0.074 pp | 0.00% +0.000 pp | USD2.51 +45.8% | 3 qtrs — |
| 23 | MAN GROUP PLC | 52.7K +52.7K (+100.0%) | 192.7K +192.7K (+100.0%) | 0.19% +0.193 pp | 0.00% +0.000 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 24 | INTEGRATED WEALTH CONCEPTS LLC | 51.0K -17.0K (-25.0%) | 186.7K -64.6K (-25.7%) | 0.19% -0.066 pp | 0.00% +0.000 pp | USD1.95 +87.7% | 9 qtrs — |
| 25 | QUADRATURE CAPITAL LTD | 49.1K +49.1K (+100.0%) | 179.7K +179.7K (+100.0%) | 0.18% +0.180 pp | 0.00% +0.002 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 26 | PVG ASSET MANAGEMENT CORP | 38.8K -34.4K (-47.0%) | 142.0K -128.3K (-47.5%) | 0.14% -0.130 pp | 0.30% -0.693 pp | USD1.56 +134.6% | 7 qtrs — |
| 27 | GSA CAPITAL PARTNERS LLP | 36.1K +36.1K (+100.0%) | 132.0K +132.0K (+100.0%) | 0.13% +0.132 pp | 0.01% +0.011 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 28 | CHOREO, LLC | 36.3K +— (+0.0%) | 129.8K -4.2K (-3.1%) | 0.13% -0.002 pp | 0.00% 0.000 pp | USD3.01 +21.6% | 9 qtrs — |
| 29 | PFG INVESTMENTS, LLC | 34.7K +6.3K (+22.1%) | 127.0K +22.0K (+20.9%) | 0.13% +0.022 pp | 0.01% +0.001 pp | USD2.19 +67.1% | 8 qtrs — |
| 30 | NEWEDGE ADVISORS, LLC | 32.5K +20.1K (+162.3%) | 119.1K +73.2K (+159.9%) | 0.12% +0.073 pp | 0.00% +0.000 pp | USD3.04 +20.4% | 3 qtrs — |
| 31 | TWO SIGMA ADVISERS, LP | 25.3K +25.3K (+100.0%) | 92.4K +92.4K (+100.0%) | 0.09% +0.093 pp | 0.00% +0.000 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 32 | ENVESTNET ASSET MANAGEMENT INC | 23.5K +1.2K (+5.5%) | 86.0K +3.7K (+4.5%) | 0.09% +0.003 pp | 0.00% +0.000 pp | USD2.09 +75.1% | 9 qtrs — |
| 33 | UBS GROUP AG | 23.1K -7.2K (-23.7%) | 84.6K -27.3K (-24.4%) | 0.08% -0.028 pp | 0.00% +0.000 pp | USD1.90 +92.6% | 5 qtrs — |
| 34 | WEAVER CONSULTING GROUP | 19.5K -1.1K (-5.2%) | 71.5K -4.7K (-6.1%) | 0.07% -0.005 pp | 0.02% -0.002 pp | USD1.64 +123.2% | 7 qtrs — |
| 35 | ABACUS PLANNING GROUP, INC. | 14.5K +— (+0.0%) | 53.2K -509.0 (-0.9%) | 0.05% -0.001 pp | 0.01% 0.000 pp | USD3.70 -1.1% | 2 qtrs — |
| 36 | XTX TOPCO LTD | 14.4K +14.4K (+100.0%) | 52.8K +52.8K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.001 pp | USD3.66 +0.0% | 5 qtrs — |
| 37 | PRUDENTIAL FINANCIAL INC | 13.0K -133.0 (-1.0%) | 47.7K -947.0 (-1.9%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD2.07 +76.8% | 7 qtrs — |
| 38 | VISIONARY WEALTH ADVISORS | 11.2K +11.2K (+100.0%) | 41.1K +41.1K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.002 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 39 | FORUM FINANCIAL MANAGEMENT, LP | 10.0K +10.0K (+100.0%) | 36.6K +36.6K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.001 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 7.6K -18.6K (-71.2%) | 27.6K -44.1K (-61.4%) | 0.03% -0.070 pp | 0.00% 0.000 pp | USD1.99 +83.9% | 9 qtrs — |
| 41 | WELLS FARGO & COMPANY/MN | 5.0K +— (+0.0%) | 18.3K -175.0 (-0.9%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD3.70 -1.1% | 9 qtrs — |
| 42 | MTM INVESTMENT MANAGEMENT, LLC | 4.2K +4.2K (+100.0%) | 15.6K +15.6K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.005 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 43 | SRS CAPITAL ADVISORS, INC. | 4.1K +2.0K (+95.9%) | 15.0K +7.2K (+94.0%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD3.68 -0.5% | 2 qtrs — |
| 44 | NATIONAL BANK OF CANADA /FI/ | 2.4K -23.1K (-90.6%) | 8.8K -85.4K (-90.7%) | 0.01% -0.086 pp | 0.00% 0.000 pp | USD2.94 +24.5% | 3 qtrs — |
| 45 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 2.4K -4.4K (-64.7%) | 8.8K -16.3K (-65.0%) | 0.01% -0.017 pp | 0.00% 0.000 pp | USD3.70 -1.1% | 2 qtrs — |
| 46 | MORGAN STANLEY | 2.2K -299.0 (-12.2%) | 7.9K -1.2K (-13.0%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.84 +98.9% | 9 qtrs — |
| 47 | JPMORGAN CHASE & CO | 672.00 +— (+0.0%) | 2.5K -23.0 (-0.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.01 +21.6% | 9 qtrs — |
| 48 | WOLVERINE ASSET MANAGEMENT LLC | 600.00 +— (+0.0%) | 2.2K -21.0 (-0.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.70 -1.1% | 2 qtrs — |
| 49 | BANK OF AMERICA CORP /DE/ | 459.00 -6.7K (-93.6%) | 1.7K -24.6K (-93.6%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD3.60 +1.7% | 9 qtrs — |
| 50 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 33.00 +— (+0.0%) | 121.00 -1.0 (-0.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.27 +61.2% | 9 qtrs — |
| 51 | LARSON FINANCIAL GROUP LLC | 16.00 +16.0 (+100.0%) | 59.00 +59.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.63 +0.8% | 1 qtrs NEW |
| 52 | BNP PARIBAS ARBITRAGE, SNC | 2.00 +— (+0.0%) | 7.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 +144.0% | 8 qtrs — |
| 53 | ACADIAN ASSET MANAGEMENT LLC | — -43.1K (-100.0%) | — -158.0K (-100.0%) | 0.00% -0.160 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
| 54 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | — -4.8K (-100.0%) | — -17.8K (-100.0%) | 0.00% -0.018 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 55 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 56 | SCIENTECH RESEARCH LLC | — -18.1K (-100.0%) | — -66.8K (-100.0%) | 0.00% -0.067 pp | 0.00% -0.023 pp | USD— | 2 qtrs SOLD |
| 57 | MACQUARIE GROUP LTD | — -6.7K (-100.0%) | — -25.0K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 58 | SIMPLEX TRADING, LLC | — -54.5K (-100.0%) | — -201.0K (-100.0%) | 0.00% -0.203 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 59 | HRT FINANCIAL LP | — -46.1K (-100.0%) | — -170.0K (-100.0%) | 0.00% -0.172 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 60 | SWAN CAPITAL LLC | — -250.0 (-100.0%) | — -924.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 61 | TME FINANCIAL, INC. | — -11.5K (-100.0%) | — -42.5K (-100.0%) | 0.00% -0.043 pp | 0.00% -0.032 pp | USD— | 4 qtrs SOLD |
| 62 | TOTH FINANCIAL ADVISORY CORP | — -400.0 (-100.0%) | — -1.5K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 63 | TOWER RESEARCH CAPITAL LLC (TRC) | — -4.8K (-100.0%) | — -17.7K (-100.0%) | 0.00% -0.018 pp | 0.00% -0.001 pp | USD— | 9 qtrs SOLD |
| 64 | FMR LLC | — -63.0 (-100.0%) | — -233.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 65 | TWO SIGMA SECURITIES, LLC | — -30.5K (-100.0%) | — -112.6K (-100.0%) | 0.00% -0.113 pp | 0.00% -0.017 pp | USD— | 3 qtrs SOLD |
| 66 | CITIGROUP INC | — -525.0 (-100.0%) | — -1.9K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 67 | OMERS ADMINISTRATION CORP | — -17.7K (-100.0%) | — -65.4K (-100.0%) | 0.00% -0.066 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 290.9K | 0.60% |
| 2 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.00% | 57.4K | 0.47% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 766.0K | 0.05% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 839.83 | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.1K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 11.4K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.94M | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.3K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.3K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 936.25 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
3.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,967
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Jin David | Officer | A-Award | A | Common Stock, par value $0.001 | 2,967 | 2.18 | 6.5K | 1,251,571 | D | ↗ |
| 2026-03-18 | WEISS MICHAEL S | Director / Officer | A-Award | A | common stock, par value $0.001 | 475,424 | 0.00 | — | 2,276,562 | D | ↗ |
| 2026-03-18 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common stock, par value $0.001 | 475,424 | 0.00 | — | 4,586,841 | D | ↗ |
| 2026-01-01 | Lorenz Kevin | Director | A-Award | A | common stock, par value $0.001 | 27,322 | 0.00 | — | 101,009 | D | ↗ |
| 2026-01-01 | LOBELL J JAY | Director | A-Award | A | common stock, par value $0.001 | 27,322 | 0.00 | — | 192,397 | D | ↗ |
| 2026-01-01 | Klein Dov | Director | A-Award | A | common stock, par value $0.001 | 27,322 | 0.00 | — | 130,105 | D | ↗ |
| 2026-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock, par value $0.001 | 27,322 | 0.00 | — | 115,747 | D | ↗ |
| 2026-01-01 | Harvey Jimmie | Director | A-Award | A | common stock, par value $0.001 | 27,322 | 0.00 | — | 146,704 | D | ↗ |
| 2025-10-01 | Jin David | Officer | A-Award | A | Common Stock, par value $0.001 | 2,711 | 1.31 | 3.5K | 1,248,604 | D | ↗ |
| 2025-04-01 | Jin David | Officer | A-Award | A | Common Stock, par value $0.001 | 5,000 | 1.22 | 6.1K | 1,245,893 | D | ↗ |
| 2025-01-01 | WEISS MICHAEL S | Director / Officer | A-Award | A | common stock, par value $0.001 | 454,153 | 0.00 | — | 1,801,138 | D | ↗ |
| 2025-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common stock, par value $0.001 | 454,153 | 0.00 | — | 4,111,417 | D | ↗ |
| 2025-01-01 | Lu Lucy | Director | A-Award | A | common stock, par value $0.001 | 49,383 | 0.00 | — | 61,273 | D | ↗ |
| 2025-01-01 | Lorenz Kevin | Director | A-Award | A | common stock, par value $0.001 | 49,383 | 0.00 | — | 73,687 | D | ↗ |
| 2025-01-01 | Klein Dov | Director | A-Award | A | common stock, par value $0.001 | 49,383 | 0.00 | — | 102,783 | D | ↗ |
| 2025-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock, par value $0.001 | 49,383 | 0.00 | — | 88,425 | D | ↗ |
| 2025-01-01 | Harvey Jimmie | Director | A-Award | A | common stock, par value $0.001 | 49,383 | 0.00 | — | 119,382 | D | ↗ |
| 2024-12-19 | Jin David | Officer | A-Award | A | Common Stock, par value $0.001 | 1,000,000 | 0.00 | — | 1,240,893 | D | ↗ |
| 2024-10-01 | Jin David | Officer | A-Award | A | Common Stock, par value $0.001 | 2,625 | 1.23 | 3.2K | 240,893 | D | ↗ |
| 2024-09-23 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common stock, par value $0.001 | 763,359 | 1.84 | 1.40M | 3,657,264 | D | ↗ |
| 2024-07-11 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | 7.48 | 37.4K | 127,500 | — | ↗ |
| 2024-07-10 | Jin David | Officer | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 500 | 7.50 | 3.8K | 500 | — | ↗ |
| 2024-07-09 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | 7.39 | 37.0K | 122,500 | — | ↗ |
| 2024-07-08 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | 7.35 | 36.8K | 117,500 | — | ↗ |
| 2024-06-28 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 20,000 | 1.64 | 32.7K | 2,893,905 | — | ↗ |
| 2024-05-20 | Klein Dov | Director | S-Sale | D | COMMON STOCK, PAR VALUE $0.001 | 10,000 | 1.89 | 18.9K | 53,400 | — | ↗ |
| 2024-05-16 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 10,000 | 1.76 | 17.6K | 2,873,905 | — | ↗ |
| 2024-04-01 | Jin David | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 2,352 | 1.70 | 4.0K | 238,268 | — | ↗ |
| 2024-01-05 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 2.38 | 118.8K | 2,863,905 | — | ↗ |
| 2024-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 216,465 | 0.00 | — | 1,346,985 | — | ↗ |
| 2024-01-01 | Rowinsky Eric K | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 6,666 | 0.00 | — | 68,797 | — | ↗ |
| 2024-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 216,465 | 0.00 | — | 2,813,905 | — | ↗ |
| 2024-01-01 | Lu Lucy | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 3,333 | 0.00 | — | 11,890 | — | ↗ |
| 2024-01-01 | Lorenz Kevin | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 3,333 | 0.00 | — | 24,304 | — | ↗ |
| 2024-01-01 | LOBELL J JAY | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 6,666 | 0.00 | — | 115,692 | — | ↗ |
| 2024-01-01 | Klein Dov | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 6,666 | 0.00 | — | 63,400 | — | ↗ |
| 2024-01-01 | Hoenlein Malcolm | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 3,333 | 0.00 | — | 39,042 | — | ↗ |
| 2024-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 6,666 | 0.00 | — | 69,999 | — | ↗ |
| 2023-12-20 | Jin David | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 140,000 | 0.00 | — | 235,916 | — | ↗ |
| 2023-11-14 | WEISS MICHAEL S | Director / Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 147,058 | 1.70 | 250.0K | 1,130,520 | — | ↗ |
| 2023-11-14 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 1,567,515 | 1.70 | 2.66M | 2,597,440 | — | ↗ |
| 2023-09-26 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.28 | 28.3K | 15,449,091 | — | ↗ |
| 2023-08-18 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 10,000 | 9.34 | 93.4K | 112,500 | — | ↗ |
| 2023-08-17 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 10,000 | 11.75 | 117.5K | 102,500 | — | ↗ |
| 2023-02-10 | WEISS MICHAEL S | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 1,197,604 | 0.84 | 1,000.0K | 14,752,034 | — | ↗ |
| 2023-02-10 | Rowinsky Eric K | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 11,976 | 0.84 | 10.0K | 931,976 | — | ↗ |
| 2023-02-10 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 2,395,209 | 0.84 | 2.00M | 15,349,091 | — | ↗ |
| 2023-02-10 | Lu Lucy | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 11,976 | 0.84 | 10.0K | 133,379 | — | ↗ |
| 2023-02-10 | LOBELL J JAY | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 299,401 | 0.84 | 250.0K | 1,635,401 | — | ↗ |
| 2023-02-10 | Jin David | Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 35,928 | 0.84 | 30.0K | 1,438,757 | — | ↗ |
| 2023-01-01 | WEISS MICHAEL S | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,219,294 | 0.00 | — | 13,554,430 | — | ↗ |
| 2023-01-01 | Rowinsky Eric K | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 920,000 | — | ↗ |
| 2023-01-01 | ROSENWALD LINDSAY A MD | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,219,294 | 0.00 | — | 12,953,882 | — | ↗ |
| 2023-01-01 | Lu Lucy | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 121,403 | — | ↗ |
| 2023-01-01 | Lorenz Kevin | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 314,572 | — | ↗ |
| 2023-01-01 | LOBELL J JAY | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 1,336,000 | — | ↗ |
| 2023-01-01 | Klein Dov | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 851,015 | — | ↗ |
| 2023-01-01 | Hoenlein Malcolm | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 535,636 | — | ↗ |
| 2023-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 950,000 | — | ↗ |
| 2022-12-16 | Lu Lucy | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 30,000 | 0.00 | — | 71,403 | — | ↗ |
| 2022-12-14 | Lu Lucy | Director | — | D | Common Stock | 0 | 0.00 | — | 36,403 | — | ↗ |
| 2022-12-01 | ROSENWALD LINDSAY A MD | Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.68 | 68.0K | 11,730,324 | — | ↗ |
| 2022-11-30 | ROSENWALD LINDSAY A MD | Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 5,000 | 0.56 | 2.8K | 11,630,324 | — | ↗ |
| 2022-11-30 | Jin David | Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 5,000 | 0.56 | 2.8K | 1,402,829 | — | ↗ |
| 2022-10-26 | Jin David | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,350,000 | 0.00 | — | 1,397,829 | — | ↗ |
| 2022-10-21 | ROSENWALD LINDSAY A MD | Officer | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.70 | 69.5K | 11,625,324 | — | ↗ |
| 2022-08-16 | Jin David | Officer | — | D | Common Stock | 0 | 0.00 | — | 47,829 | — | ↗ |
| 2022-06-01 | ROSENWALD LINDSAY A MD | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 4,264 | 0.73 | 3.1K | 11,734,588 | — | ↗ |
| 2022-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,102,986 | 0.00 | — | 12,335,136 | — | ↗ |
| 2022-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 820,000 | — | ↗ |
| 2022-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,102,986 | 0.00 | — | 11,525,324 | — | ↗ |
| 2022-01-01 | Lorenz Kevin | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 264,572 | — | ↗ |
| 2022-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 1,236,000 | — | ↗ |
| 2022-01-01 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 751,015 | — | ↗ |
| 2022-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 485,636 | — | ↗ |
| 2022-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 850,000 | — | ↗ |
| 2021-12-28 | Klein Dov | Director | S-Sale | D | Common Stock, par value $0.001 | 5,000 | 2.45 | 12.3K | 651,015 | — | ↗ |
| 2021-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,250 | 2.42 | 3.0K | 10,422,338 | — | ↗ |
| 2021-11-16 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | J-Other | A | COMMON STOCK, PAR VALUE $0.001 | 4,619 | 0.00 | — | 10,421,088 | — | ↗ |
| 2021-11-16 | Klein Dov | Director | J-Other | A | Common Stock, par value $0.001 | 230 | 0.00 | — | 656,015 | — | ↗ |
| 2021-11-16 | Hoenlein Malcolm | Director | J-Other | A | Common Stock | 230 | 0.00 | — | 435,636 | — | ↗ |
| 2021-09-30 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | J-Other | A | COMMON STOCK, PAR VALUE $0.001 | 8,133 | 0.00 | — | 10,416,469 | — | ↗ |
| 2021-09-30 | Klein Dov | Director | J-Other | A | Common Stock, par value $0.001 | 480 | 0.00 | — | 655,785 | — | ↗ |
| 2021-09-30 | Hoenlein Malcolm | Director | J-Other | A | Common Stock | 406 | 0.00 | — | 435,406 | — | ↗ |
| 2021-09-21 | Hunter Robyn | Officer | S-Sale | D | Common Stock, par value $0.001 | 28,292 | 3.13 | 88.6K | 163,877 | — | ↗ |
| 2021-08-05 | Klein Dov | Director | J-Other | A | Common Stock, par value $0.001 | 305 | 0.00 | — | 655,305 | — | ↗ |
| 2021-06-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,297 | 2.31 | 3.0K | 10,408,336 | — | ↗ |
| 2021-03-02 | Rowinsky Eric K | Director | S-Sale | D | Common Stock, par value $0.001 | 10,000 | 4.45 | 44.5K | 720,000 | — | ↗ |
| 2021-02-19 | Rowinsky Eric K | Director | S-Sale | D | Common Stock, par value $0.001 | 8,000 | 4.31 | 34.5K | 730,000 | — | ↗ |
| 2021-02-18 | Rowinsky Eric K | Director | S-Sale | D | Common Stock, par value $0.001 | 6,000 | 4.20 | 25.2K | 738,000 | — | ↗ |
| 2021-02-16 | Rowinsky Eric K | Director | S-Sale | D | Common Stock, par value $0.001 | 2,000 | 3.86 | 7.7K | 744,000 | — | ↗ |
| 2021-02-05 | Rowinsky Eric K | Director | S-Sale | D | Common Stock, par value $0.001 | 4,000 | 3.80 | 15.2K | 746,000 | — | ↗ |
| 2021-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,030,339 | 0.00 | — | 11,232,150 | — | ↗ |
| 2021-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 750,000 | — | ↗ |
| 2021-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,030,339 | 0.00 | — | 10,407,039 | — | ↗ |
| 2021-01-01 | Lorenz Kevin | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 214,582 | — | ↗ |
| 2021-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 1,136,000 | — | ↗ |
| 2021-01-01 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 655,000 | — | ↗ |
| 2021-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 435,000 | — | ↗ |
| 2021-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 750,000 | — | ↗ |
| 2020-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,250 | 2.34 | 2.9K | 9,376,700 | — | ↗ |
| 2020-09-22 | Hunter Robyn | Officer | S-Sale | D | Common Stock, par value $0.001 | 28,450 | 4.38 | 124.6K | 192,169 | — | ↗ |
| 2020-08-26 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 52,500 | 18.00 | 945.0K | 92,500 | — | ↗ |
| 2020-08-26 | Hoenlein Malcolm | Director | P-Purchase | A | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 16,667 | 18.00 | 300.0K | 16,667 | — | ↗ |
| 2020-06-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 1,602 | 1.69 | 2.7K | 9,375,450 | — | ↗ |
| 2020-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 801,536 | 0.00 | — | 10,201,811 | — | ↗ |
| 2020-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 650,000 | — | ↗ |
| 2020-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 801,536 | 0.00 | — | 9,373,848 | — | ↗ |
| 2020-01-01 | Lorenz Kevin | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 50,000 | 0.00 | — | 164,582 | — | ↗ |
| 2020-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 1,036,000 | — | ↗ |
| 2020-01-01 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 555,000 | — | ↗ |
| 2020-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 385,000 | — | ↗ |
| 2020-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 650,000 | — | ↗ |
| 2019-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 1,123 | 2.06 | 2.3K | 8,572,312 | — | ↗ |
| 2019-08-14 | Lorenz Kevin | Director | — | D | Common Stock, par value $0.001 | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2019-07-18 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 396,825 | 1.26 | 500.0K | 8,569,722 | — | ↗ |
| 2019-06-03 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK, PAR VALUE $0.001 | 1,467 | 1.10 | 1.6K | 8,571,189 | — | ↗ |
| 2019-06-03 | Hunter Robyn | Officer | P-Purchase | A | Common Stock, par value $0.001 | 2,297 | 1.10 | 2.5K | 220,619 | — | ↗ |
| 2019-04-17 | Avgerinos George | Officer | A-Award | A | Options to purchase Common Stock | 200,000 | 9.21 | 1.84M | 200,000 | — | ↗ |
| 2019-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 648,204 | 0.00 | — | 9,400,275 | — | ↗ |
| 2019-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 550,000 | — | ↗ |
| 2019-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock | 648,204 | 0.00 | — | 8,172,897 | — | ↗ |
| 2019-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 936,000 | — | ↗ |
| 2019-01-01 | Klein Dov | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 455,000 | — | ↗ |
| 2019-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 335,000 | — | ↗ |
| 2019-01-01 | Harvey Jimmie | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 100,000 | 0.00 | — | 550,000 | — | ↗ |
| 2018-12-11 | Avgerinos George | Officer | S-Sale | D | COMMON STOCK, PAR VALUE $0.001 | 97,325 | 1.05 | 102.2K | 255,170 | — | ↗ |
| 2018-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,514 | 0.00 | — | 7,524,693 | — | ↗ |
| 2018-11-23 | Hunter Robyn | Officer | S-Sale | D | Common Stock | 20,370 | 1.29 | 26.3K | 239,759 | — | ↗ |
| 2018-07-03 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 164,473 | 0.00 | — | 8,752,071 | — | ↗ |
| 2018-07-03 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock | 164,473 | 0.00 | — | 7,523,179 | — | ↗ |
| 2018-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 586,428 | 0.00 | — | 8,587,598 | — | ↗ |
| 2018-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 450,000 | — | ↗ |
| 2018-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock | 586,428 | 0.00 | — | 7,358,706 | — | ↗ |
| 2018-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 786,000 | — | ↗ |
| 2018-01-01 | Klein Dov | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 355,000 | — | ↗ |
| 2018-01-01 | Hoenlein Malcolm | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 285,000 | — | ↗ |
| 2018-01-01 | Harvey Jimmie | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 450,000 | — | ↗ |
| 2017-12-14 | Avgerinos George | Officer | S-Sale | D | COMMON STOCK, PAR VALUE $0.001 | 12,000 | 3.55 | 42.6K | 352,495 | — | ↗ |
| 2017-12-13 | Avgerinos George | Officer | S-Sale | D | COMMON STOCK, PAR VALUE $0.001 | 19,000 | 3.57 | 67.8K | 364,495 | — | ↗ |
| 2017-12-12 | Avgerinos George | Officer | S-Sale | D | COMMON STOCK, PAR VALUE $0.001 | 25,593 | 3.59 | 91.9K | 383,495 | — | ↗ |
| 2017-11-29 | Avgerinos George | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.001 | 150,000 | 0.00 | — | 409,088 | — | ↗ |
| 2017-11-06 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | SERIES A CUMULATIVE REDEEMABLE PERPETUAL PREFERRED STOCK | 40,000 | 25.00 | 1.00M | 40,000 | — | ↗ |
| 2017-07-14 | Klein Dov | Director | D-Return | D | Common Stock, par value $0.001 | 13,333 | 0.00 | — | 201,668 | — | ↗ |
| 2017-06-26 | Hunter Robyn | Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 260,129 | — | ↗ |
| 2017-03-10 | Hoenlein Malcolm | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 49,998 | — | ↗ |
| 2017-03-10 | Harvey Jimmie | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 49,998 | — | ↗ |
| 2017-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.001 | 552,698 | 0.00 | — | 8,001,170 | — | ↗ |
| 2017-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 350,000 | — | ↗ |
| 2017-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.001 | 552,698 | 0.00 | — | 5,857,168 | — | ↗ |
| 2017-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 686,000 | — | ↗ |
| 2017-01-01 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 241,667 | — | ↗ |
| 2017-01-01 | Hoenlein Malcolm | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 33,332 | — | ↗ |
| 2017-01-01 | Harvey Jimmie | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 33,332 | — | ↗ |
| 2016-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 731 | 2.03 | 1.5K | 5,304,470 | — | ↗ |
| 2016-09-16 | Avgerinos George | Officer | S-Sale | D | Common Stock, par value $0.001 | 33,912 | 2.55 | 86.5K | 259,088 | — | ↗ |
| 2016-09-15 | Avgerinos George | Officer | S-Sale | D | Common Stock, par value $0.001 | 15,000 | 2.54 | 38.1K | 293,000 | — | ↗ |
| 2016-09-14 | Avgerinos George | Officer | A-Award | A | Common Stock, par value $0.001 | 150,000 | 0.00 | — | 308,000 | — | ↗ |
| 2016-09-12 | FBIO Acquisition, Inc. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 16,294 | — | ↗ |
| 2016-07-15 | Klein Dov | Director | A-Award | A | Deferred Restricted Stock Units | 13,333 | 0.00 | — | 13,333 | — | ↗ |
| 2016-06-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 613 | 2.40 | 1.5K | 5,303,739 | — | ↗ |
| 2016-05-20 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | S-Sale | D | Ordinary Shares | 1,020,000 | 0.00 | 0.97 | 265,000 | — | ↗ |
| 2016-03-16 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Convertible Promissory Note | 7,500 | 10.00 | 75.0K | 32,500 | — | ↗ |
| 2016-03-14 | Hoenlein Malcolm | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 16,666 | — | ↗ |
| 2016-03-14 | Harvey Jimmie | Director | A-Award | A | Deferred Restricted Stock Units | 16,666 | 0.00 | — | 16,666 | — | ↗ |
| 2016-02-03 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Convertible Promissory Note | 10,000 | 10.00 | 100.0K | 25,000 | — | ↗ |
| 2016-01-01 | WEISS MICHAEL S | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.001 | 510,434 | 0.00 | — | 7,448,472 | — | ↗ |
| 2016-01-01 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 250,000 | — | ↗ |
| 2016-01-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.001 | 510,434 | 0.00 | — | 5,303,126 | — | ↗ |
| 2016-01-01 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 586,000 | — | ↗ |
| 2016-01-01 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 100,000 | 0.00 | — | 155,000 | — | ↗ |
| 2015-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 586 | 2.41 | 1.4K | 4,792,692 | — | ↗ |
| 2015-10-09 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Convertible Promissory Note | 50,000 | 10.00 | 500.0K | 15,000 | — | ↗ |
| 2015-09-11 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 31,299 | 2.68 | 83.9K | 158,000 | — | ↗ |
| 2015-09-10 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 22,737 | 2.62 | 59.6K | 189,299 | — | ↗ |
| 2015-09-09 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 14,100 | 2.62 | 36.9K | 212,036 | — | ↗ |
| 2015-09-08 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 11,704 | 2.57 | 30.1K | 226,136 | — | ↗ |
| 2015-09-04 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 2,136 | 2.60 | 5.6K | 237,840 | — | ↗ |
| 2015-09-03 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 18,200 | 2.58 | 47.0K | 239,976 | — | ↗ |
| 2015-09-02 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 24,900 | 2.60 | 64.7K | 258,176 | — | ↗ |
| 2015-09-01 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 158 | 2.70 | 426.60 | 283,076 | — | ↗ |
| 2015-08-31 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 3,500 | 2.94 | 10.3K | 283,234 | — | ↗ |
| 2015-08-21 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 10,000 | 2.55 | 25.5K | 286,734 | — | ↗ |
| 2015-08-19 | Avgerinos George | Officer | D-Return | D | Common Stock, par value $0.001 | 11,266 | 3.00 | 33.8K | 296,734 | — | ↗ |
| 2015-08-13 | Avgerinos George | Officer | A-Award | A | Common Stock, par value $0.001 | 300,000 | 0.00 | — | 308,000 | — | ↗ |
| 2015-07-15 | Klein Dov | Director | A-Award | A | Common Stock, par value $0.001 | 50,000 | 0.00 | — | 55,000 | — | ↗ |
| 2015-07-15 | Avgerinos George | Officer | D-Return | D | Options to purchase Common Stock | 200,000 | 9.21 | 1.84M | 0 | — | ↗ |
| 2015-06-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 785 | 1.80 | 1.4K | 4,792,106 | — | ↗ |
| 2015-03-18 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | A-Award | A | Convertible Promissory Note | 10,000 | 10.00 | 100.0K | 10,000 | — | ↗ |
| 2015-03-12 | Rowinsky Eric K | Director | A-Award | A | Common Stock, par value $0.001 | 50,000 | 0.00 | — | 100,000 | — | ↗ |
| 2015-03-12 | LOBELL J JAY | Director | A-Award | A | Common Stock, par value $0.001 | 50,000 | 0.00 | — | 436,000 | — | ↗ |
| 2015-01-05 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | J-Other | D | Ordinary Shares | 100,000 | 0.00 | — | 1,285,000 | — | ↗ |
| 2014-12-12 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | — | I | Ordinary Shares | 0 | 0.00 | — | 1,385,000 | — | ↗ |
| 2014-12-01 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 974 | 1.45 | 1.4K | 4,791,321 | — | ↗ |
| 2014-12-01 | Lu Lucy | Officer | P-Purchase | A | Common Stock, par value $0.001 | 5,000 | 1.45 | 7.3K | 35,631 | — | ↗ |
| 2014-11-06 | WEISS MICHAEL S | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 1,000,000 | 1.61 | 1.61M | 6,938,038 | — | ↗ |
| 2014-11-06 | ROSENWALD LINDSAY A MD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 150,000 | 1.61 | 241.5K | 4,790,347 | — | ↗ |
| 2014-11-06 | Hoenlein Malcolm | Director | P-Purchase | A | Common Stock, par value $0.001 | 25,000 | 1.61 | 40.3K | 55,000 | — | ↗ |
| 2014-06-02 | Lu Lucy | Officer | P-Purchase | A | Common Stock, par value $0.001 | 5,000 | 1.37 | 6.9K | 30,631 | — | ↗ |
| 2014-04-22 | HORGAN KEVIN | Officer | S-Sale | D | Common Stock | 47,566 | 1.89 | 90.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-695.3K
Shares Outstanding
32.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2012 | Lucy Lu, M.D. Executive Vice President and Chief Financial Officer | 256.9K | 92.5K | — | 1.52M | — | 683.00 | 1.87M | 81.31% | ↗ |
| 2 | 2012 | Karin M. Hehenberger, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 300.0K | 108.0K | — | 763.8K | — | 820.00 | 1.17M | 65.13% | ↗ |
| 3 | 2012 | Bobby W. Sandage, Jr. Ph.D. President and Former Chief Executive Officer | 395.0K | 200.0K | — | — | — | 3.9K | 598.9K | 0.00% | ↗ |
| 4 | 2012 | Dale Ritter Senior Vice President, Finance and Chief Accounting Officer | 272.1K | 99.0K | — | 203.1K | — | 8.3K | 582.6K | 34.86% | ↗ |
| 5 | 2012 | Noah D. Beerman Executive Vice President and Chief Operating Officer | 328.0K | 132.8K | — | — | — | 3.8K | 464.7K | 0.00% | ↗ |
| 6 | 2012 | Harlan F. Weisman, M.D. Chairman and Chief Executive Officer | 4.6K | — | — | 120.3K | — | 13.1K | 138.0K | 87.14% | ↗ |
| 7 | 2011 | Bobby W. Sandage, Jr., Ph.D. | 284.1K | 140.0K | — | 257.3K | — | 133.9K | 815.3K | 31.55% | ↗ |
| 8 | 2011 | Bobby W. Sandage, Jr. Ph.D. President and Former Chief Executive Officer | 284.1K | 140.0K | — | 257.3K | — | 133.9K | 795.3K | 32.35% | ↗ |
| 9 | 2011 | Noah D. Beerman Executive Vice President and Chief Operating Officer | 87.5K | 39.0K | — | 484.4K | — | — | 610.9K | 79.29% | ↗ |
| 10 | 2011 | Noah D. Beerman Executive Vice President and Chief Operating Officer | 87.5K | 36.0K | — | 484.4K | — | — | 607.9K | 79.68% | ↗ |
| 11 | 2011 | Gary Gemignani Former Executive Vice President, | 177.6K | — | — | 36.5K | — | 295.2K | 509.3K | 7.17% | ↗ |
| 12 | 2011 | Karin M. Hehenberger, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 17.1K | 5.1K | — | 481.4K | — | — | 503.7K | 95.58% | ↗ |
| 13 | 2011 | Dale Ritter Senior Vice President, Finance and Chief Accounting Officer | 149.9K | 62.0K | — | 102.9K | — | 7.9K | 322.7K | 31.89% | ↗ |
| 14 | 2011 | Glenn L. Cooper, M.D. Executive Chairman, Director | 225.0K | — | — | — | — | 97.5K | 322.5K | 0.00% | ↗ |
| 15 | 2011 | Lucy Lu, M.D. Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 16 | 2011 | Harlan F. Weisman, M.D. Chairman and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 17 | 2010 | Gary Gemignani Former Executive Vice President, | 211.5K | 175.0K | — | 312.6K | — | — | 699.1K | 44.72% | ↗ |
| 18 | 2010 | Glenn L. Cooper, M.D. Executive Chairman, Director | — | — | — | 453.7K | — | 137.5K | 591.2K | 76.74% | ↗ |
| 19 | 2010 | Noah D. Beerman Executive Vice President and Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 20 | 2010 | Bobby W. Sandage, Jr. Ph.D. President and Former Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 21 | 2010 | Dale Ritter Senior Vice President, Finance and Chief Accounting Officer | — | — | — | — | — | — | — | — | ↗ |
| 22 | 2010 | Karin M. Hehenberger, M.D., Ph.D. Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 23 | 2010 | Lucy Lu, M.D. Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 24 | 2010 | Harlan F. Weisman, M.D. Chairman and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lindsay Allan Rosenwald | Executive Chairman, President & Chief Executive Officer | 687.7K | — |
| David Jin | Chief Financial Officer & Head of Corporate Development | 664.1K | male |
| Michael S. Weiss | Executive Vice Chairman of Strategic Development & Director | 652.7K | male |
| Xiaoqin Lu | Chief Strategy Officer | 15.0K | — |
| Samuel Berry | General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
